Navigation Links
Malaria treatment efficacy compromised in certain HIV-positive patients

A weakened immune response resulting from HIV infection can lead to trouble when it comes to treating malaria, according to a new study appearing in the Oct. 1 issue of The Journal of Infectious Diseases, now available online.

"Our study demonstrates that HIV-1 infected patients with suppressed immunity represent, next to children and pregnant women, an additional vulnerable group for malaria," says Jean-Pierre Van geertruyden, MD, MSc, lead author of the article.

CD4 lymphocytes, white blood cells that serve a critical role in the immune response to malaria, are also the prime target for HIV. Low CD4 cell counts are a characteristic of HIV-induced immune suppression. In this study, Dr. Van geertruyden and colleagues from the Institute of Tropical Medicine in Belgium and the Tropical Disease Research Center in Zambia show that HIV-positive patients with low CD4 cell counts tended to have an increased risk of malaria treatment failure when compared to both HIV-negative patients and HIV-positive patients with higher CD4 cell counts.

Therefore, "HIV-1 associated immune suppression, rather than infection with HIV-1 per se, is the main determinant of malaria treatment outcome," says Dr. Van geertruyden.

This finding exposes a danger that implementing new malaria combination therapies to treat the disease in immune-suppressed patients could lead to the emergence and spread of antimalarial drug resistance. "This is a major concern, as antimalarial drug resistance is now generally acknowledged to be one of the greatest threats to our ability to roll back malaria," according to Dr. Van geertruyden.

The study suggests that malaria control and prevention, next to early diagnosis and a highly efficacious malaria treatment, are essential tools in areas where both diseases coexist. Furthermore, the interaction between antimalarial and antiretroviral therapies should continue to be examined in an effort to maximize the effects of therapy on both diseases and to decrease the malaria burden in HIV-infected individuals.


'"/>

Source:Infectious Diseases Society of America


Related biology news :

1. Malaria mechanism revealed
2. Malaria killing a million a year
3. Malaria parasites develop in lymph nodes
4. Malaria, potato famine pathogen share surprising trait
5. Malaria vaccine prompts victims immune system to eliminate parasite from mosquitoes
6. Twenty Years of Malaria Research: Outcomes and Perspectives
7. Malaria may fuel spread of HIV in sub-Saharan Africa
8. Protein discovery could unlock the secret to better TB treatment
9. Topical treatment shown to inhibit HIV and herpes simplex virus infection
10. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
11. Researchers add new tool to tumor-treatment arsenal
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/22/2016)... -- SuperCom (NASDAQ:   SPCB ... Public Safety, HealthCare, and Finance sectors announced today that Leaders in ... implement and deploy a community-based supportive services program to reduce recidivism ... further expanding its presence in the state. ... This new program, which is expected to ...
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/16/2016)... The global wearable medical device market, in terms of value, is ... billion in 2016, at a CAGR of 18.0% during the forecast ... Growth ... devices, launch of a growing number of smartphone-based healthcare apps compatible ... and increasing focus on physical fitness. Furthermore, growing ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... Research and Markets ... has announced the addition of the ... 2025" report to their offering. Report ... provides a detailed analysis on current and future market trends to identify ... market values as the base numbers Key market trends ...
(Date:1/19/2017)... ANNAPOLIS, Md. and GAITHERSBURG, ... Inc. (NYSE MKT: PIP) and Altimmune, Inc., a ... the signing of a definitive agreement for the ... transaction. Altimmune,s current investors include Novartis Venture Fund, ... company will be a fully-integrated and diversified immunotherapeutics ...
(Date:1/19/2017)... , ... January 18, 2017 , ... ... Institutes of Health (NIH) to update its Data Sharing Policy. Specifically, the nation’s ... of grant applications subject to the existing policy. AMIA recommended that NIH earmark ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... services spanning the full spectrum of drug and device development, and Prism ... pharma/device companies and clinicians, today announced Verified Clinical Trials (VCT) has ...
Breaking Biology Technology: